Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 7
- Registration Number
- NCT06425003
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc., Madison, Wisconsin, United States
A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 72
- Registration Number
- NCT06310876
- Locations
- 🇺🇸
AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States
Expanded Access to ABBV-CLS-484
- Conditions
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Calico Life Sciences LLC
- Registration Number
- NCT06188975
A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 18
- Registration Number
- NCT06145607
- Locations
- 🇺🇸
AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States
A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 12
- Registration Number
- NCT05763459
- Locations
- 🇺🇸
AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States
An Open-Label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 14
- Registration Number
- NCT05757141
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of Utah Hospital, Salt Lake City, Utah, United States
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 31
- Registration Number
- NCT04948645
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Johns Hopkins ALS Clinical Trials Unit, Baltimore, Maryland, United States
🇺🇸Healey & AMG Center for ALS Research, Boston, Massachusetts, United States
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 248
- Registration Number
- NCT04777994
- Locations
- 🇺🇸
NYU Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
🇮🇱Rabin Medical Center, Petah Tikva, Hamerkaz, Israel
🇺🇸University of Arizona Cancer Center - Tucson, Tucson, Arizona, United States
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 263
- Registration Number
- NCT04417465
- Locations
- 🇺🇸
Highlands Oncology Group Springdale, Springdale, Arkansas, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States